← Back to Clinical Trials
RecruitingNCT03217396

Biomarkers of Synaptic Damage in Multiple Sclerosis

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionMultiple Sclerosis
SponsorNeuromed IRCCS
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment300
SexALL
Min Age18 Years
Max Age65 Years
Start Date2017-11-22
Completion2026-09-01
Interventions
lumbar puncture

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.

Eligibility Criteria

Inclusion Criteria: 1. Male and female patients (age between 18 and 65 years) 2. Diagnosis of MS in accordance with McDonald's (2010 rev) criteria, 3. EDSS between 0 and 5.5 (included), 4. Patients able to provide informed consent to participation in the study Exclusion Criteria: 1. Inability to provide informed written consent 2. Altered basal blood count 3. Pregnancy or lactation 4. Contraindications for the execution of magnetic resonance imaging with gadolinium 5. Significant clinical conditions in addition to SM or other chronic neurodegenerative diseases including latent viral infections

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology